The first new drug approved to treat tuberculosis (TB) since 1963 could result in shorter treatment with less side effects and the opportunity to treat more people. For people with drug-resistant TB, it could present a new lifeline.
90% of our funding comes from individual donors. Learn how you can support MSF’s lifesaving care with a gift.
Related
Related
The first new drug approved to treat tuberculosis (TB) since 1963 could result in shorter treatment with less side effects and the opportunity to treat more people. For people with drug-resistant TB, it could present a new lifeline.
© Médecins Sans Frontières 2024 Federal tax ID#: 13-3433452
Unrestricted donations enable MSF to carry out our programs around the world. If we cannot honor a specific request, we will reallocate your donation to where the needs are greatest.
For Donors
For Supporters
For Media
For Recruits
General Interest
© Médecins Sans Frontières 2024 Federal tax ID#: 13-3433452
Unrestricted donations enable MSF to carry out our programs around the world. If we cannot honor a specific request, we will reallocate your donation to where the needs are greatest.
Your gift helps us provide medical humanitarian aid for hundreds of thousands of people each year.
Learn more87%
Programs
12%
Fundraising
1%
Management & General Admin